HT-2157

From Wikipedia, the free encyclopedia
  (Redirected from SNAP-37889)
Jump to navigation Jump to search
HT-2157
Structural formula
Space-filling model
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
Chemical and physical data
FormulaC21H13F3N2O
Molar mass366.343 g·mol−1
3D model (JSmol)

HT-2157 (former development code SNAP-37889) is a drug which acts as a selective non-peptide antagonist for the receptor GAL-3, which is usually activated by the neuropeptide galanin. Blocking this receptor with HT-2157 produced increased serotonin release,[1] as well as producing antidepressant and anxiolytic effects in animal studies,[2] and it was also being researched for treatment of cognitive dysfunction.[3] All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.[4]

References[edit]

  1. ^ "pA2 Online". www.pa2online.org.
  2. ^ Swanson, C. J.; Blackburn, T. P.; Zhang, X.; Zheng, K.; Xu, Z.-Q. D.; Hokfelt, T.; Wolinsky, T. D.; Konkel, M. J.; Chen, H.; Zhong, H.; Walker, M. W.; Craig, D. A.; Gerald, C. P. G.; Branchek, T. A. (2005). "Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299". Proceedings of the National Academy of Sciences. 102 (48): 17489–17494. doi:10.1073/pnas.0508970102. PMC 1283534. PMID 16287967.
  3. ^ US 8277842, Kaplan AP, "Enteric-coated HT-2157 compositions and methods of their use", published January 20, 2012 
  4. ^ "Dart NeuroScience LLC -- Scientific Advisory Board". www.dartneuroscience.com.